Twist Bioscience (NASDAQ:TWST) Price Target Raised to $40.00

Twist Bioscience (NASDAQ:TWST) had its price target boosted by JPMorgan Chase & Co. from $35.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has an underweight rating on the stock.

TWST has been the topic of a number of other reports. Scotiabank increased their price target on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research report on Tuesday. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. TD Cowen reiterated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird increased their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.80.

Twist Bioscience Trading Up 0.1 %

Twist Bioscience stock opened at $53.70 on Tuesday. Twist Bioscience has a 1 year low of $27.41 and a 1 year high of $60.90. The company has a market cap of $3.19 billion, a PE ratio of -14.92 and a beta of 1.87. The company’s 50-day moving average is $48.84 and its two-hundred day moving average is $46.32.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same period in the prior year, the company posted ($0.75) EPS. The company’s revenue was up 24.1% compared to the same quarter last year. Research analysts forecast that Twist Bioscience will post -2.27 EPS for the current year.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 5,200 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $256,620.00. Following the completion of the transaction, the chief executive officer now directly owns 667,318 shares of the company’s stock, valued at $32,932,143.30. This trade represents a 0.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 806 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $39,776.10. Following the transaction, the insider now directly owns 112,221 shares of the company’s stock, valued at $5,538,106.35. This represents a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 59,002 shares of company stock valued at $2,851,681. 3.01% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience during the 3rd quarter worth approximately $34,000. Van ECK Associates Corp grew its stake in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares in the last quarter. Signaturefd LLC grew its stake in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares in the last quarter. US Bancorp DE grew its stake in shares of Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after buying an additional 601 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC bought a new position in shares of Twist Bioscience in the third quarter valued at $95,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.